GeoVax Labs Inc
NASDAQ:GOVX

Watchlist Manager
GeoVax Labs Inc Logo
GeoVax Labs Inc
NASDAQ:GOVX
Watchlist
Price: 0.19 USD -8.21% Market Closed
Market Cap: 5.6m USD

GeoVax Labs Inc
Total Equity

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

GeoVax Labs Inc
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
GeoVax Labs Inc
NASDAQ:GOVX
Total Equity
$4.9m
CAGR 3-Years
-46%
CAGR 5-Years
-15%
CAGR 10-Years
10%
Abbvie Inc
NYSE:ABBV
Total Equity
-$2.6B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Gilead Sciences Inc
NASDAQ:GILD
Total Equity
$21.5B
CAGR 3-Years
1%
CAGR 5-Years
4%
CAGR 10-Years
2%
Amgen Inc
NASDAQ:AMGN
Total Equity
$9.6B
CAGR 3-Years
38%
CAGR 5-Years
-3%
CAGR 10-Years
-10%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Total Equity
$17.3B
CAGR 3-Years
10%
CAGR 5-Years
16%
CAGR 10-Years
34%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Total Equity
$31B
CAGR 3-Years
13%
CAGR 5-Years
25%
CAGR 10-Years
25%
No Stocks Found

GeoVax Labs Inc
Glance View

Market Cap
5.6m USD
Industry
Biotechnology

GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of immunotherapies and vaccines against cancers and infectious diseases using a novel vector vaccine platform. The company is headquartered in Smyrna, Georgia. The firm is focused on developing human vaccines and immunotherapies against infectious diseases and cancer using its platforms. Its product pipeline includes ongoing human clinical trials for COVID-19 and head and neck cancer. The firm is developing a number of vaccines and immunotherapies for prevention or treatment of infectious diseases and cancers. The Company’s product candidate includes GEO-CM04S1, GEO-CM02, Gedeptin, MVA-VLP-MUC1, GEO-ZM02, GEO-EM01, GEO-LM01 and GEO-MM02. Its research and development programs include preventive vaccines against Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa) and malaria, as well as immunotherapies for multiple solid tumors. The Company’s wholly owned subsidiaries include GeoVax, Inc. and Immutak Oncology, Inc.

GOVX Intrinsic Value
Not Available

See Also

What is GeoVax Labs Inc's Total Equity?
Total Equity
4.9m USD

Based on the financial report for Sep 30, 2025, GeoVax Labs Inc's Total Equity amounts to 4.9m USD.

What is GeoVax Labs Inc's Total Equity growth rate?
Total Equity CAGR 10Y
10%

Over the last year, the Total Equity growth was -42%. The average annual Total Equity growth rates for GeoVax Labs Inc have been -46% over the past three years , -15% over the past five years , and 10% over the past ten years .

Back to Top